DUBLIN--(BUSINESS WIRE)--The "Duloxetine HCl Market Insights 2019, Analysis and Forecast Global and Chinese Market to 2024, by Manufacturers, Product Type, Application, Regions and Technology" report ...

INDIANAPOLIS, July 6, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has met the United States Food and Drug Administration (FDA) requirements for pediatric exclusivity ...

NAPERVILLE, Ill., July 08, 2020 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc., a privately-held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and ...

Sept. 9, 2004 — The U.S. Food and Drug Administration (FDA) has approved duloxetine HCl for the management of diabetic neuropathic pain, a qualified health claim for reduced risk of coronary heart ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The FDA recently approved duloxetine ...

The Division of Drug Marketing, Advertising, and Communications (DDMAC) of the U.S. Food and Drug Administration (FDA) has reviewed a professional mailer (mailer) (DD38459) for CYMBALTA® (duloxetine ...

November 30, 2009 — The US Food and Drug Administration (FDA) has approved an expanded indication for duloxetine HCl (Cymbalta delayed-release capsules, Eli Lilly & Company, Inc) for the maintenance ...

INDIANAPOLIS, Jan. 30 /PRNewswire-FirstCall/ -- In a new study, Cymbalta (duloxetine HCl) 60-120 mg, taken once daily, reduced pain severity significantly, compared ...

The Food and Drug Administration recently approved Cymbalta (duloxetine hydrochloride) to treat chronic musculoskeletal pain, including discomfort from osteoarthritis and chronic lower back pain. The ...

Lilly announced that Cymbalta (duloxetine HCl) has gained an indication for the management of chronic musculoskeletal pain, including chronic osteoarthritis pain and chronic low back pain. Although ...